BREAST CANCER AND BMI: ROLE OF L-CARNITINE IN PREDICTION OF ANSWER TO TREATMENT AND OUTCOME OF TUMOR IN PATIENTS WITH OBESITY

doi:10.4066/2249-622X-C3-009

BREAST CANCER AND BMI: ROLE OF L-CARNITINE IN PREDICTION OF ANSWER TO TREATMENT AND OUTCOME OF TUMOR IN PATIENTS WITH OBESITY

Joint Event on International Conference on PHARMACEUTICS AND NOVEL DRUG DELIVERY SYSTEMS & 19^th International Conference on CELLULAR AND MOLECULAR MEDICINE & 19^th Annual Congress on PSYCHIATRY AND PSYCHIATRIC DISORDERS
October 19-20 , 2018 | Tokyo , Japan

Hojouj M I M

Dnipropetrovsk Medical Academy, Ukraine

Posters & Accepted Abstracts : Asian J Biomed Pharmaceut Sci

DOI: 10.4066/2249-622X-C3-009

Abstract:

Increasing the effectiveness of antitumor therapy in breast cancer patients who take L-carnitine during preoperative systemic antitumor therapy compared with patients receiving standard neoadjuvant systemic antitumor therapy served as a prerequisite for studying possi-ble antitumor mechanisms of L-carnitine. The positive effect of L-carnitine is due to the trans-fer of palm-n-fatty acid through the inner membrane into the mitochondrial matrix, which contributes to the formation of a significant number of ATP molecules. It has also been shown that L-carnitine can have a double protective effect, enhancing the energy dynamics of the cell and inhibiting the hyperexcitability of the cell membrane, making it an ideal tool for the prevention and treatment of complications of antitumor therapy and concomitant metabolic disorders. This work summarizes the results of epidemiological and clinical studies on the use of L-carnitine in the treatment of breast cancer.

Biography:

PDF HTML